Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells

Neuro-Oncology

Volumn 16, Issue 4, 2014, Pages 552-566

  Fang, Kuan Min ^a   Yang, Chung Shi ^b   Lin, Tzu Chien ^a   Chan, Ti Chun ^a   Tzeng, Shun Fen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Chemokine (C C motif) ligand 7; Glioma; Interleukin 33; Microglia; ST2

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; PROTEIN; PROTEIN ST2; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL INFILTRATION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE ONTOLOGY; GENE SILENCING; GENETIC ANALYSIS; GLIOMA CELL; GROWTH RATE; HUMAN; HUMAN CELL; LENTIVIRINAE; MACROPHAGE; MICROGLIA; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

CHEMOKINE (C-C MOTIF) LIGAND 7; GLIOMA; INTERLEUKIN-33; MICROGLIA; ST2;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; IMMUNOENZYME TECHNIQUES; INTERLEUKINS; LENTIVIRUS; MICE; MICROGLIA; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84897003843     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not234     Document Type: Article

References (51)

1. Robins HI, Peterson CG, Mehta MP. Combined modality treatment for central nervous system malignancies. Semin Oncol. 2003; 30(4 suppl 9):11-22.
2. Watters JJ, Schartner JM, Badie B. Microglia function in brain tumors. J Neurosci Res. 2005;81(3):447-455.
3. Lam-Himlin D, Espey MG, Perry G, Smith MA, Castellani RJ. Malignant glioma progression and nitric oxide. Neurochem Int. 2006;49(8): 764-768.
4. Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron. 2008;58(6):832-846.
5. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152-1160.
6. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007;25(26):4033-4042.
7. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003;22(31):4918-4923.
8. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001;61(18):6885-6891.
9. Vitucci M, Hayes DN, Miller CR. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer. 2011;104(4):545-553.
10. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63(7):1602-1607.
11. Dieterich LC, Mellberg S, Langenkamp E, et al. Transcriptional profilingof human glioblastomavessels indicates a key role of VEGF-Aand TGFbeta2 in vascular abnormalization. J Pathol. 2012;228(3):378-390.
12. Pen A, Moreno MJ, Martin J, Stanimirovic DB. Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia. 2007;55(6):559-572.
13. Beaty RM, Edwards JB, Boon K, Siu IM, Conway JE, Riggins GJ. PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol. 2007;81(3):241-248.
14. Grobben B,De Deyn PP, Slegers H. Rat C6glioma as experimentalmodel system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;310(3):257-270.
15. Auer RN, Del Maestro RF, Anderson R. A simple and reproducible experimental in vivo gliomamodel. Can J Neurol Sci. 1981;8(4):325-331.
16. Tzeng SF, Lee JL, Kuo JS, et al. Effects of malonate C60 derivatives on activated microglia. Brain Res. 2002;940(1-2):61-68.
17. Fang KM,Wang YL, Huang MC, Sun SH, Cheng H, Tzeng SF. Expression of macrophage inflammatory protein-1alpha and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: involvement of ATP and P2X(7) receptor. J Neurosci Res. 2011;89(2):199-211.
18. Liu YP, Yang CS, Tzeng SF. Inhibitory regulation of glutamate aspartate transporter (GLAST) expression in astrocytes by cadmium-induced calcium influx. J Neurochem. 2008;105(1):137-150.
19. Lin YL, Tsai MJ, Lo MJ, et al. Evaluation of the antiangiogenic effect of Kringle 1-5 in a rat glioma model. Neurosurgery. 2012;70(2): 479-489; discussion 489-490.
20. Fu YS, Lin YY, Chou SC, et al. Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: potential therapeutic application for treatment of gliomas. Neuro Oncol. 2008; 10(2):139-152.
21. Yasuoka S, Kawanokuchi J, Parajuli B, et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011;1385:8-17.
22. OkadaM, Saio M, Kito Y, et al. Tumor-associatedmacrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol. 2009;34(6):1621-1627.
23. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60(17):4926-4931.
24. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375-4381.
25. Turini ME, DuBois RN. Cyclooxygenase-2: atherapeutic target. AnnuRev Med. 2002;53:35-57.
26. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24(8):792-799.
27. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266.
28. Ping YF, Yao XH, Jiang JY, et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol. 2011;224(3): 344-354.
29. Bian XW, Yang SX, Chen JH, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery. 2007;61(3): 570-578; discussion 578-579.
30. Hattermann K, Held-Feindt J, Lucius R, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 2010;70(8):3299-3308.
31. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009;75(5):1240-1247.
32. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012;21(3):341-353.
33. Iwami K, Natsume A, Wakabayashi T. Cytokine networks in glioma. Neurosurg Rev. 2011;34(3):253-263; discussion 263-254.
34. Streit WJ,Conde JR, Fendrick SE, Flanary BE, Mariani CL.Role of microglia in the central nervous system's immune response. Neurol Res. 2005; 27(7):685-691.
35. Zhu VF, Yang J, Lebrun DG, Li M. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett. 2012;316(2): 139-150.
36. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol. 2009;30(5):227-233.
37. REMBRANDT. REpository for Molecular BRAin Neoplasia Data. National Cancer Institute. 2005. http://rembrandt.nci.nih.gov (accessed Septermber 28, 2013).
38. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev. 2010;10(2):103-110.
39. Zhou Y, Zhang J, Liu Q, et al. The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. Carcinogenesis. 2005;26(12): 2058-2068.
40. Tang P, Steck PA, Yung WK. The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol. 1997;35(3):303-314.
41. Junier MP. What role(s) for TGFalpha in the central nervous system? Prog Neurobiol. 2000;62(5):443-473.
42. Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A. Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol. 2009;19(3):163-170.
43. Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol. 2011;12(12):2150-2157.
44. Weissenberger J, Loeffler S, Kappeler A, et al. IL-6 is required for glioma development in a mouse model. Oncogene. 2004;23(19):3308-3316.
45. Wang CC, Fang KM, Yang CS, Tzeng SF. Reactive oxygen species-induced cell death of rat primary astrocytes through mitochondria-mediated mechanism. J Cell Biochem. 2009;107(5):933-943.
46. Kabashima K, Sugita K, Shiraishi N, Tamamura H, Fujii N, Tokura Y. CXCR4 engagement promotesdendritic cell survivalandmaturation. Biochem Biophys Res Commun. 2007;361(4):1012-1016.
47. Honczarenko M, Le Y, Glodek AM, et al. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood. 2002;100(7):2321-2329.
48. Wang X, Li C, Chen Y, et al. Hypoxia enhancesCXCR4expression favoring microglia migration via HIF-1alpha activation. Biochem Biophys Res Commun. 2008;371(2):283-288.
49. Lu DY, Tang CH, Yeh WL, et al. SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaB-dependent pathway in microglia. Eur J Pharmacol. 2009;613(1-3):146-154.
50. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci. 2001;4(7):702-710.
51. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22.